



News Release

Media Contact:

Dennis Fortier

Phone: (949) 838-0154 x388

Email: dfortier@mccare.com

STUDY DEMONSTRATES ACCURACY OF MCI SCREEN FOR EARLY DETECTION OF MEMORY LOSS DUE TO VARIOUS MEDICAL CONDITIONS

A study conducted at the Fukuoka University Hospital in Japan demonstrated the validity of the Japanese MCI Screen (**J-MCIS**) for accurately identifying early signs of memory loss. The study showed that the J-MCIS Screen has better predictive power than neuro-imaging methods such as MRI and SPECT for identifying people with underlying neurological conditions. This study was published in the April/May issue of American Journal of Alzheimer's Disease and Other Dementias.

The MCI Screen (**MCIS**), developed by Medical Care Corporation, employs sophisticated mathematical scoring methods to evaluate complex recall patterns to detect early signs of memory impairment due to various medical conditions including Alzheimer's disease and related disorders. The MCI Screen has published accuracy of 97% for distinguishing normal aging from mild cognitive impairment, and been used in both academic and community settings for research and clinical purposes in the USA.

In this study, a total of 63 patients who are either aging normally (N=8) or had mild cognitive impairment (N=48) were recruited from the Fukuoka University Hospital memory clinic. These patients and their caregiver informants were interviewed to obtain a comprehensive medical history and they were evaluated for major depressive disorder following which, seven were excluded from the further analyses. A total of 56 patients were evaluated with the J-MCIS, Mini Mental State Exam (MMSE), SPECT (qSPECT) and/or MRI (qMRI) with volumetric analysis. For subjects with mild cognitive impairment, underlying medical conditions included Alzheimer's disease, lewy body disease, and frontal-temporal lobe degeneration. The results showed that accuracies for distinguishing normal from mild cognitive impairment for the J-MCIS and MMSE were 96% and 77%, respectively, replicating earlier results using the MCIS in the USA. The results also showed that the J-MCIS had 20% more predictive power than qSPECT and qMRI for distinguishing normal aging vs. mild cognitive impairment.

“These results indicate the stability of MCC's scoring technology across different cultures and settings which both expands the number of people we can help and extends the business opportunity for our company”, said Dennis Fortier, president and CEO of

Medical Care Corporation. “The J-MCIS having better predictive power than neuro-imaging is not surprising to us since neuro-imaging is strictly used to diagnose underlying medical conditions, and not to predict the stage of any particular disease. In rapidly aging countries like the USA and Japan, accurately and economically identifying patients who require further medical attention is critical. Doing so enables timely intervention and more effective treatment while minimizing unnecessary and expensive medical works ups like neuro-imaging. The MCIS and J-MCIS are positioned to provide a sound solution to the growing financial burden associated with Alzheimer’s disease and related disorders.”

About Medical Care Corporation

Medical Care Corporation develops highly comprehensive dementia care products for healthcare professionals. Their technology enables accurate identification and effective management of memory loss from its earliest stages onward. The company’s MCI Screen is 97.3% accurate in distinguishing a pre-dementia stage called mild cognitive impairment (MCI) from normal aging. The company is also a leader in communicating the value of prevention and early detection to patients and caregivers through its website and educational materials. Additional information about the company is available at two websites: For Health Care Providers: www.mccare.com; For Patients and Caregivers: www.preventad.com